Literature DB >> 27487101

Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Jean-Francois H Geschwind1, Julius Chapiro1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27487101

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  4 in total

Review 1.  Locoregional and systemic therapy for hepatocellular carcinoma.

Authors:  Olumide B Gbolahan; Michael A Schacht; Eric W Beckley; Thomas P LaRoche; Bert H O'Neil; Maximilian Pyko
Journal:  J Gastrointest Oncol       Date:  2017-04

2.  Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.

Authors:  Jason Pe; Bongseo Choi; Hyunjun Choi; Soon Woo Kwon; Dong-Hyun Kim
Journal:  Cardiovasc Intervent Radiol       Date:  2022-08-12       Impact factor: 2.797

3.  Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial-mesenchymal transition.

Authors:  Chuntao Tian; Ying Liu; Lingfei Xue; Dong Zhang; Xiaotong Zhang; Jing Su; Jiaohong Chen; Xiangke Li; Liuxing Wang; Shunchang Jiao
Journal:  Open Life Sci       Date:  2022-06-15       Impact factor: 1.311

4.  Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.

Authors:  Shohei Yokota; Tomohiro Yonezawa; Yasuyuki Momoi; Shingo Maeda
Journal:  J Vet Med Sci       Date:  2022-04-05       Impact factor: 1.105

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.